Labnovation Spotlights HbA1c and Alzheimer’s Blood-Based Testing Solutions
Posted on 30 Jul 2026
Labnovation Technologies (Shenzhen, China) is highlighting diabetes management and Alzheimer’s disease testing at the ADLM 2026 Clinical Lab Expo in Anaheim, California. At booth 2469, the company is presenting a complete HbA1c testing portfolio alongside a blood-based approach intended to support earlier and more accessible assessment of Alzheimer’s disease.
The HbA1c portfolio includes three platforms designed for testing environments ranging from high-throughput laboratories to point-of-care settings. The systems are intended to provide laboratories with different combinations of speed, capacity, precision, and workflow flexibility for diabetes diagnosis and long-term glycemic monitoring.
For laboratories processing larger testing volumes, the LD-600 delivers HbA1c results in approximately 70 seconds per test, with a stated coefficient of variation of 1% or less. The system is positioned as the high-throughput option within the company’s ADLM showcase.
The compact LD-560 is designed for laboratories with moderate sample volumes and provides results in approximately 90 seconds per test, also with a stated coefficient of variation of 1% or less. The automated analyzer uses high-performance liquid chromatography for HbA1c measurement.
Completing the portfolio is the LD-100, a point-of-care-ready analyzer that generates results in under three minutes with a stated coefficient of variation of 2.5% or less. Its compact format is intended to extend HbA1c testing beyond centralized laboratories to smaller clinical and decentralized care settings.
Labnovation is additionally presenting a blood-based testing solution for Alzheimer’s disease. The company introduces the approach as a noninvasive and accessible option that uses a simple blood draw to support earlier detection.
